Zimmer Biomet Holdings Inc (NYSE: ZBH) has reported E.P.S. of $1.18 for its second fiscal quarter (ending June 30) versus $1.00 for the same period a year ago — an increase of 18%. Relative to the consensus estimate of $1.99, this was a shortfall of $-0.81. For the latest four quarters through June 30, E.P.S. were $4.82 compared to $2.42 a year ago — an increase of 99%.
Recent Price Action
Zimmer Biomet Holdings Inc (NYSE: ZBH) stock closed at $105.81 on 8/7/24 after a decline of -3.4%. Moreover, this decline was accompanied by unusually high trading volume at 184% of normal. The stock has declined -5.0% during the last week and has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to exceed the cost of capital, ZBH is expected to continue to be an important Value Builder.
Zimmer Biomet Holdings has a current Value Trend Rating of D (Negative). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Zimmer Biomet Holdings has a neutral Appreciation Score of 40 and a slightly negative Power Rating of 32, producing the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment